142 related articles for article (PubMed ID: 8453625)
41. In vivo modulation of cisplatin cytotoxicity by the cholecystokinin antagonist MK-329 in human pancreatic cancer xenografts.
Jamshidipour R; Pinho EB; Howell SB
Anticancer Res; 1994; 14(6B):2611-6. PubMed ID: 7872689
[TBL] [Abstract][Full Text] [Related]
42. Tamoxifen: is it useful in the treatment of patients with metastatic melanoma?
McClay EF; McClay ME
J Clin Oncol; 1994 Mar; 12(3):617-26. PubMed ID: 8120562
[TBL] [Abstract][Full Text] [Related]
43. Enhancement of the cytotoxicity of cisplatin by the cholecystokinin antagonist MK-329 in a human pancreatic cancer cell line.
Jamshidipour R; Pinho EB; Hom DK; Howell SB
Cancer Chemother Pharmacol; 1994; 34(6):484-90. PubMed ID: 7923559
[TBL] [Abstract][Full Text] [Related]
44. Modulation of cisplatin resistance by 2'-deoxy-5-azacytidine in human ovarian tumor cell lines.
Lenzi R; Frost P; Abbruzzese JL
Anticancer Res; 1994; 14(1A):247-51. PubMed ID: 7513143
[TBL] [Abstract][Full Text] [Related]
45. Synergistic interaction between cisplatin and tamoxifen delays the emergence of cisplatin resistance in head and neck cancer cell lines.
Nakata B; Albright KD; Barton RM; Howell SB; Los G
Cancer Chemother Pharmacol; 1995; 35(6):511-8. PubMed ID: 7882460
[TBL] [Abstract][Full Text] [Related]
46. Effects of anticancer agents on the shedding of cells from human multicellular tumor spheroids.
Kohno N; Ohnuma T; Holland JF; Biller H
Invasion Metastasis; 1987; 7(5):264-74. PubMed ID: 3679741
[TBL] [Abstract][Full Text] [Related]
47. Tamoxifen and 5-fluorouracil in breast cancer: modulation of cellular RNA.
Benz C; Santos G; Cadman E
Cancer Res; 1983 Nov; 43(11):5304-8. PubMed ID: 6616465
[TBL] [Abstract][Full Text] [Related]
48. [Studies on sensitivity test with clonogenic assay against chemo-endocrine therapy for human breast cancer].
Hamada Y
Nihon Geka Gakkai Zasshi; 1985 Apr; 86(4):411-23. PubMed ID: 4000099
[TBL] [Abstract][Full Text] [Related]
49. Evaluation of the effect of paclitaxel, epirubicin and tamoxifen by cell kinetics parameters in estrogen-receptor-positive ehrlich ascites tumor (eat) cells growing in vitro.
Ozcan Arican G; Ozalpan A
Acta Biol Hung; 2007 Mar; 58(1):49-59. PubMed ID: 17385543
[TBL] [Abstract][Full Text] [Related]
50. Modulation of ganglioside expression in human melanoma cell lines; increased resistance to chemo- and radiation treatment.
Kunitomo K; Irie RF; Kern DH
Tokushima J Exp Med; 1992 Jun; 39(1-2):55-62. PubMed ID: 1384169
[TBL] [Abstract][Full Text] [Related]
51. Growth effects of tamoxifen on Lovo colon carcinoma cells and cultured cells from normal colonic mucosa.
Lointier P; Wildrick DM; Boman BM
Anticancer Res; 1992; 12(5):1523-5. PubMed ID: 1444215
[TBL] [Abstract][Full Text] [Related]
52. Calmodulin antagonism and growth-inhibiting activity of triphenylethylene antiestrogens in MCF-7 human breast cancer cells.
Gulino A; Barrera G; Vacca A; Farina A; Ferretti C; Screpanti I; Dianzani MU; Frati L
Cancer Res; 1986 Dec; 46(12 Pt 1):6274-8. PubMed ID: 3022916
[TBL] [Abstract][Full Text] [Related]
53. Effect of sequential application of hyperthermia and chemotherapy on the survival of a thermoresistant human melanoma cell line.
Greco C; Cavaliere R; Giovanella B; Natali PG; Zupi G
Cancer Biochem Biophys; 1987 Sep; 9(3):223-32. PubMed ID: 3435895
[TBL] [Abstract][Full Text] [Related]
54. Bromodeoxyuridine improves the cytotoxic effect of cisplatin: a comparison with 5-fluorouracil.
Chelladurai M; Lobocki CA; Sultani M; Hanna Y; Drelichman A; Pieper DR; McLaughlin PW
Cancer Chemother Pharmacol; 1997; 40(6):463-8. PubMed ID: 9332459
[TBL] [Abstract][Full Text] [Related]
55. Combination effects of cis-dichlorodiammineplatinum with selected metahalones, pyrimidine sulfoxides and pyrimidine sulfones on human NHIK 3025 cells in vitro.
Dornish JM; Undheim K; Pettersen EO; Oftebro R; Laland SG
Anticancer Drug Des; 1988 Dec; 3(3):191-8. PubMed ID: 3207466
[TBL] [Abstract][Full Text] [Related]
56. The combination of glutamate receptor antagonist MK-801 with tamoxifen and its active metabolites potentiates their antiproliferative activity in mouse melanoma K1735-M2 cells.
Ribeiro MP; Nunes-Correia I; Santos AE; Custódio JB
Exp Cell Res; 2014 Feb; 321(2):288-96. PubMed ID: 24240127
[TBL] [Abstract][Full Text] [Related]
57. Perturbation of in vitro drug resistance in human lymphatic neoplasms by combinations of putative inhibitors of protein kinase C.
Weisenthal LM; Su YZ; Duarte TE; Dill PL; Nagourney RA
Cancer Treat Rep; 1987 Dec; 71(12):1239-43. PubMed ID: 3480042
[TBL] [Abstract][Full Text] [Related]
58. Tamoxifen-induced cell death in malignant melanoma cells: possible involvement of the insulin-like growth factor-1 (IGF-1) pathway.
Kanter-Lewensohn L; Girnita L; Girnita A; Dricu A; Olsson G; Leech L; Nilsson G; Hilding A; Wejde J; Brismar K; Larsson O
Mol Cell Endocrinol; 2000 Jul; 165(1-2):131-7. PubMed ID: 10940491
[TBL] [Abstract][Full Text] [Related]
59. The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma.
McClay EF; Mastrangelo MJ; Sprandio JD; Bellet RE; Berd D
Cancer; 1989 Apr; 63(7):1292-5. PubMed ID: 2920358
[TBL] [Abstract][Full Text] [Related]
60. A survey of human breast cancer sensitivity to growth inhibition by calmodulin antagonists in tissue culture.
Strobl JS; Peterson VA; Woodfork KA
Biochem Pharmacol; 1994 Jun; 47(12):2157-61. PubMed ID: 8031308
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
